Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The FDA has approved Metastatix's application to test MSX-122, a CXCR4 inhibitor that the company is developing for the treatment of a number of critical indications, including various cancers and inflammatory diseases.
Subscribe to our email newsletter
The investigational new drug application (IND) acceptance will permit Metastatix to commence Phase I clinical studies in the US to determine the safety and tolerability of MSX-122 for the treatment of solid tumors.
Using technology licensed from Emory University, combined with world-class expertise in medicinal chemistry, Metastatix said that it is developing a robust portfolio of chemical compounds that block the CXCR4 receptor.
Carol Gallagher, president and CEO of Metastatix, said: “The credit for Metastatix’s rapid development path goes to our very talented team. We are very pleased to have produced a viable candidate for treating a disease as devastating as cancer in the two years since the company’s founding.”